Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On January 9, 2026, Tiziana Life Sciences announced that CEO Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum in San Francisco on January 11, 2026, held during J.P. Morgan Healthcare Conference Week, with senior management also attending for one-on-one meetings with investors, partners and other stakeholders. The company plans to use this high-profile neuroscience event—focused on advances in therapeutics, neurotechnology and diagnostics—to spotlight clinical progress and data for its lead candidate intranasal foralumab in non-active secondary progressive multiple sclerosis, including signals of disease stability or improvement in an expanded access program and an ongoing Phase 2a trial, underscoring Tiziana’s bid to strengthen its positioning in neuroinflammatory and neurodegenerative markets and deepen engagement with potential strategic and financial partners.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing breakthrough immunotherapies using transformational drug delivery technologies, particularly intranasal delivery, as alternatives to traditional intravenous administration. Its lead product candidate is intranasal foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development, which has shown a favorable safety profile and clinical responses in patients to date and is being advanced for neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis (na-SPMS).
Average Trading Volume: 294,307
Technical Sentiment Signal: Hold
Current Market Cap: $178.3M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.